Heron Therapeutics (HRTX) Misses Q1 EPS by 15c

Heron Therapeutics (NASDAQ: HRTX) reported Q1 EPS of ($0.63), $0.15 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $22.4 million versus the consensus estimate of $22.61 million.

GUIDANCE:

Heron Therapeutics sees FY2022 revenue of $89-93 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Morgan Stanley Starts Adani Enterprises Ltd. (ADE:IN) at Overweight
• AeroVironment restates quarterly financials, citing $89M goodwill error